Kyle joined MVM in 2017. Prior to joining, he was a consultant at Bain & Company, working mainly in the healthcare practice to support medical device and healthcare provider clients. During his undergraduate and graduate education, Kyle was a prolific researcher and writer, publishing a half-dozen peer-reviewed papers on topics ranging from homologous chromosome pairing genetics to orthopedic surgery outcomes. Kyle completed MD studies at Harvard Medical School and MBA studies at Harvard Business School. He also holds an AB in biochemistry from Bowdoin College.

Kyle is a board director of Optinose, Inc. (NASDAQ:OPTN), HLS Therapeutics Inc. (TSX: HLS), and GT Medical Technologies, Inc.; he is also an observer on the board of MDxHealth SA (NASDAQ: MDXH). He was previously a board observer of Biotheranostics, Inc. (acquired by Hologic).